Phase separation-induced nuclear organization in ALT Cancer

Information

  • Research Project
  • 10260573
  • ApplicationId
    10260573
  • Core Project Number
    U01CA260851
  • Full Project Number
    5U01CA260851-02
  • Serial Number
    260851
  • FOA Number
    RFA-RM-20-006
  • Sub Project Id
  • Project Start Date
    9/10/2020 - 3 years ago
  • Project End Date
    8/31/2025 - a year from now
  • Program Officer Name
    MIETZ, JUDY
  • Budget Start Date
    9/1/2021 - 2 years ago
  • Budget End Date
    8/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    8/31/2021 - 2 years ago

Phase separation-induced nuclear organization in ALT Cancer

Abstract: All cancer cells need to maintain telomere length for immortality. While most cancer cells reactivate telomerase, a reverse transcriptase, to elongates telomere from an RNA template, about 10-15% of cancer cells are telomerase-negative and adopt a homologous-recombination based alternative lengthening of telomeres (ALT) pathway. ALT cells exhibit many abnormalities in nuclear organization, including the formation of nuclear bodies called APBs for ALT telomere-associated promyelocytic leukemia nuclear bodies, clustering of telomeres within APBs, and the formation of RNA foci on telomeres with a long non-coding RNA called telomere repeat-containing RNA (TERRA). These unique features are used as biomarkers for ALT diagnosis and can be attractive therapeutic targets because of reduced side effects on healthy cells that do not share these features. However, how these features contribute to telomere maintenance and ALT cancer cell growth remain elusive, due to the lack of conceptual model as well as experimental tools to monitor and control their assembly and function in live cells. Based on our observation that APBs exhibit liquid behavior and long non- coding RNAs can phase separate with RNA-binding proteins, we propose a liquid-liquid phase separation model for the assmembly and function of these ALT specific features. We hypothesize TERRA phase separates with its interacting proteins to nucleate APB liquid droplets. The liquid nature of APBs droplets (also called condensates) would promote coalescence of APBs to drive telomere clustering. Meanwhile, condensation of APB droplets can concentrate DNA repair factors, providing opportunities for telomeres to use one another as repair templates to elongate within APBs. To test our hypothesis, we developed a state-of-the- art optogenetic approach to control APB assembly. We demonstrate that liquid phase separation underlies APB assembly and coalescence of APB droplets indeed drives telomere clustering. Building on our ability to control telomere clustering and APB assembly and by collaborating with experts in super resolution microscopy, nuclear mechanics, chromosome organization and ALT cancer, we will investigate how DNA repair factors are recruited to and organized in APB condensates for ALT telomere DNA synthesis (Aim 1) and how telomere clustering leads to unique genome organization and gene expression in ALT cells (Aim 2). We will then extend our optogenetic tools to control RNA and dissect TERRA contributions in ALT (Aim 3). Results obtained by manipulating cultured ALT cells will be confirmed by characterizing ALT tissue or creating de novo ALT phonotypes in primary human cells. Our results will provide mechanistic understanding on how protein and/or RNA phase separation contributes to ALT cancer, which will offer the potential to develop strategies specifically targeting these unique phase separation processes, rather than the existing molecules that shared by heathy cells, for ALT cancer treatment. Such therapies are also beneficial for treating telomerase-positive cancer as these cancer cells can escape telomerase inhibition and adopt ALT for telomere maintenance.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    U01
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
    381110
  • Indirect Cost Amount
    149838
  • Total Cost
    530948
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    310
  • Ed Inst. Type
    SCHOOLS OF ARTS AND SCIENCES
  • Funding ICs
    OD:530948\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CARNEGIE-MELLON UNIVERSITY
  • Organization Department
    BIOLOGY
  • Organization DUNS
    052184116
  • Organization City
    PITTSBURGH
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    152133815
  • Organization District
    UNITED STATES